{"ticker": {"uuid": "9fe7289d-7088-4a48-9abf-a371ff3ee490", "symbol": "XBIO", "name": "Xenetic Biosciences Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to book forward of Xenetic Biosciences, Inc. \u2013 NASDAQ:XBIO", "summary": "This page from TradingView displays financial information for Xenetic Biosciences, Inc. (NASDAQ: XBIO), specifically focusing on its \"Price to book forward\" metric. The content indicates that market data is provided by ICE Data Services, reference data by FactSet, and SEC filings", "url": "https://www.tradingview.com/symbols/NASDAQ-XBIO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T16:10:49", "published_display": "09 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Xenetic Biosciences, Inc. \u2013 NASDAQ:XBIO", "summary": "This article provides a financial data point for Xenetic Biosciences, Inc. (NASDAQ: XBIO), specifically its \"Price to sales forward\" metric. The content indicates that the market was closed at the time of viewing, with no trades apparent. It appears to be a snapshot from a financ", "url": "https://www.tradingview.com/symbols/NASDAQ-XBIO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T04:10:42", "published_display": "09 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences (XBIO) Surges 6.14% as Stock Tests Key Resistance at $3.09 - Large Cap Trends", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPN29tRDFpTzBkUU4zVW82dGp2S0hOZi1MUEp6NzBRa1NvbnZxd3VhZ1dDWDdVUEMzQ2dKdS1tXzktNVJ2TU1PUEU4V3BVVHR5cmpaM1F6ODJYSDNFcmVZcFlsSXpMOE1GWE9XR1YwcDEyT2gwcWpGZFFjM25qLUR1NEl3Qkd4aFVMbTJET2lYekZ6clhCbmtkQXo5c29ONVg3S3lrTTRWeWJGckR0RG53Wm5BTTNwSkk?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-06T15:47:40+00:00", "published_display": "06 Jul 2026 15:47", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIO - Xenetic Biosciences Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial overview for Xenetic Biosciences Inc. (XBIO). It includes key financial metrics, performance indicators, insider ownership details, and analyst recommendations. The data highlights the company's valuation, p", "url": "https://finviz.com/stock?t=XBIO&ta=1&p=d&ty=lf&r=ytd&page=3", "source_name": "Finviz", "published_at": "2026-07-04T10:40:19", "published_display": "04 Jul 2026 10:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIO - Xenetic Biosciences Inc Short Interest", "summary": "This article provides a detailed financial overview and short interest data for Xenetic Biosciences Inc. (XBIO). It includes key metrics such as market capitalization, income, sales, various ratios, and performance indicators spanning different timeframes, along with short intere", "url": "https://finviz.com/stock?t=XBIO&p=d&ty=si&r=ytd", "source_name": "Finviz", "published_at": "2026-07-04T09:40:19", "published_display": "04 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences, Inc. Actuals & Estimates (NASDAQ:XBIO)", "summary": "This article provides an overview of Xenetic Biosciences, Inc. (NASDAQ: XBIO) financials, including its current stock price, market capitalization, and earnings information. It highlights recent stock performance, historical highs and lows, and key financial metrics like EBITDA a", "url": "https://www.tradingview.com/symbols/NASDAQ-XBIO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:54", "published_display": "25 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Xenetic Biosciences Inc (XBIO) has a current risk assessment score of 1.12, ranking 328 out of 387 in the Biotechnology & Medical Research industry. The company's beta is 2.12, indicating higher volatility compared to the S&P 500. Key risk metrics like maximum drawdown and volati", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-24T05:39:56", "published_display": "24 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Xenetic Biosciences Inc (XBIO), detailing its business segments, regional revenue, and profit contribution. However, the company has not yet disclosed the relevant data for these categories. The article includes current stock informat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/revenue", "source_name": "TradingKey", "published_at": "2026-06-23T19:39:40", "published_display": "23 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Xenetic Biosciences Inc (XBIO) has a robust financial status with a current financial score of 8.34, ranking 48th in the Biotechnology & Medical Research industry. The company reported a significant year-over-year revenue increase of 36.01% to $806.92K and a net profit increase o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T08:11:02", "published_display": "23 Jun 2026 08:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Xenetic Biosciences Inc (XBIO), including its price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 26, 2026, XBIO's stock price shows a current momentum score of 6.82 and is t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/technical", "source_name": "TradingKey", "published_at": "2026-06-23T06:40:26", "published_display": "23 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences (Nasdaq:XBIO) - Stock Analysis", "summary": "Xenetic Biosciences (Nasdaq:XBIO) is a biopharmaceutical company focusing on immune-oncology technologies to treat cancers, with a market capitalization of US$6.4 million. The company has reported recent improvements in reducing net losses and growing revenue in its recent quarte", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xbio/xenetic-biosciences", "source_name": "Simply Wall Street", "published_at": "2026-06-21T04:10:48", "published_display": "21 Jun 2026 04:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Xenetic Biosciences Inc (XBIO). It notes that XBIO has distributed $0.00 in dividends over the past five years and lists stock split events, all of which were a 10-for-1 merger occurring on May 12, 2023. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T08:40:12", "published_display": "19 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Xenetic Biosciences Inc (XBIO), highlighting its current valuation score of 7.62 within the Biotechnology & Medical Research industry. It notes the company's current P/E ratio is -2.53, which is significantly below its recent high. Th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:23", "published_display": "18 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Institutional Confidence", "summary": "Xenetic Biosciences Inc (XBIO) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. Institutional shareholding proportion decreased by 53.00% quarter-over-quarter to 4.97%. James Simons is the largest insti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:23", "published_display": "18 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Xenetic Biosciences Inc (XBIO), noting that no earnings forecast score is currently available, unlike the industry average. It also details current stock performance, market capitalization, and various financial metrics. The company ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:21", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: Narrowed Loss Beats Expectations, Pipeline Progress Key - Operating Income Trends", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOMkdPSEgwNHJvZHo4Zmo0dl9rczZMd1EzREkxOER5VVNZT1VzTm1oZ3lnWi1mNVRNeUp1VkpaczNwc0NmWnF4bUFDQl92SGU3QmpmcW5GWEFYTzdGUWVMYWVWeC1RTWFOaGJGY0dNak9SeDhqWW5HbUd6aXpwOFMtNE9KYWloRWlHdTFqc0g5ei03TTh4QVNSczRjak9OWldGQmhBUlhsUVlsSm1vbGNobnNVT2tDdDV6VkVzOExYX2pMS1VZY2R4LWpkcFJ0V2ZPREo3dVIyTEVGOGpqUkE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences | 8-K: Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform", "summary": "This document is an 8-K filing from Xenetic Biosciences, reporting its financial results for the first quarter of 2026. The filing highlights the continued advancement of the company's DNase Oncology Platform. As an 8-K, it typically contains information deemed material or import", "url": "https://www.moomoo.com/news/notice/307292323/xenetic-biosciences-8-k-xenetic-biosciences-reports-first-quarter-2026", "source_name": "Moomoo", "published_at": "2026-06-06T22:10:24", "published_display": "06 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma", "summary": "Xenetic Biosciences announced that its partner, PeriNess Ltd., received approval from the Israeli Ministry of Health to conduct an exploratory clinical study. This study will combine systemic DNase I with anti-CD19 CAR T cells in patients with large B-cell lymphoma (LBCL). The ap", "url": "https://www.marketscreener.com/news/xenetic-biosciences-inc-announces-that-its-collaboration-partner-received-approval-from-the-israel-ce7f5ddcde81f52d", "source_name": "www.marketscreener.com", "published_at": "2026-06-06T03:08:59", "published_display": "06 Jun 2026 03:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Israeli study to combine DNase I with CAR-T in large B-cell lymphoma", "summary": "Xenetic Biosciences' partner, PeriNess, has received approval from the Israeli Ministry of Health to conduct an exploratory clinical study combining systemic DNase I with anti-CD19 CAR T cells for large B-cell lymphoma (LBCL) patients. The trial, to be conducted at Tel-Aviv Soura", "url": "https://www.stocktitan.net/news/XBIO/xenetic-biosciences-inc-announces-that-its-collaboration-partner-dgcaoxvrgx4y.html", "source_name": "Stock Titan", "published_at": "2026-06-04T12:39:36", "published_display": "04 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival", "summary": "Xenetic Biosciences announced positive preclinical data at ASCO 2026, showing that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancer models. The findings demonstrate DNase I's potential as a transformative ad", "url": "https://www.biospace.com/press-releases/xenetic-biosciences-showcases-compelling-asco-2026-data-demonstrating-dnase-i-significantly-enhances-car-t-cell-persistence-tumor-control-and-survival", "source_name": "BioSpace", "published_at": "2026-06-02T21:09:23", "published_display": "02 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic presents preclinical data on DNase I with CAR-T therapy", "summary": "Xenetic Biosciences Inc. presented preclinical data showing that DNase I enhances CAR-T cell expansion and antitumor efficacy in hematologic cancer models. The studies demonstrated that DNase I degrades extracellular DNA, preserves CAR-T cell function, and improves tumor control,", "url": "https://www.investing.com/news/company-news/xenetic-presents-preclinical-data-on-dnase-i-with-cart-therapy-93CH-4719450", "source_name": "Investing.com", "published_at": "2026-06-01T13:09:33", "published_display": "01 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After CAR-T failure, DNase I tied to tumor decline in pediatric lymphoma case", "summary": "Xenetic Biosciences (NASDAQ: XBIO) presented preclinical and translational data at ASCO 2026 showing that its DNase I significantly improved CAR-T cell expansion, persistence, and tumor control in aggressive B cell malignancy models. The data also include observations from a pedi", "url": "https://www.stocktitan.net/news/XBIO/xenetic-biosciences-showcases-compelling-asco-2026-data-fq1m366f597g.html", "source_name": "Stock Titan", "published_at": "2026-06-01T13:09:32", "published_display": "01 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences (XBIO) Q2 2025 Earnings: EPS Surprises to the Upside with Narrower-Than-Expected Loss - Revenue Recognition Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQdFJKbUFja2Q0TEJNNDdxOGxnRlJVWUF2ZHJQUkRFUElNNXBDMXBhSUZqdE9PTkJScmwtd2tyYmJVdmJzMUFWV0NXZzBIeXlLVG1sTnhhT1cxRjJnQWdtX2dQUXU1ek9QSXRCQ2VMVUxSUEdQYTRNaWZRdWlYSFBaV05Qd0FOdTFiVkMwRHBsaFphSXV0bjMzV0ZYMzhzbnRSTUNSZE9takN6WU1CbS1Uc2Q0aENQYnhvYTZRNHJRbm9WNC1KLU5hQjVDR0xnR2VIeXBwYjlSdXRrQ193cDdMTHpnTQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIO - Xenetic Biosciences Inc Stock Price and Quote", "summary": "This page provides a comprehensive overview of Xenetic Biosciences Inc. (XBIO) stock, including its latest financial data, recent news, and analyst ratings. It details the company's financial performance, stock statistics, and a chronological list of press releases related to its", "url": "https://finviz.com/stock?t=XBIO", "source_name": "Finviz", "published_at": "2026-05-30T19:39:40", "published_display": "30 May 2026 19:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Michael Liu and MJL Manager LLC report stakes in Xenetic Biosciences (NASDAQ: XBIO)", "summary": "Michael Liu and MJL Manager LLC have reported their stakes in Xenetic Biosciences (NASDAQ: XBIO) through a Schedule 13G filing. MJL Manager LLC holds 93,565 shares, representing 4.1% of the class, while Michael Liu individually holds 126,741 shares, accounting for 5.5%. Michael L", "url": "https://www.stocktitan.net/sec-filings/XBIO/schedule-13g-xenetic-biosciences-inc-passive-investment-disclosure-5-93ca949c0c13.html", "source_name": "Stock Titan", "published_at": "2026-05-29T19:39:20", "published_display": "29 May 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences (XBIO) Edges Lower Amid Tight Trading Range - KAMA Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPUWNxWW9iMmFlV1JENnRqM3JoNGp0QTl3QUk2aDc2cjA1LV9GYTZxM0lENERhX1dtOF9JYWlUM2IySjJRTm5UWWJGdFUxaHFqM0NmbEwzdC1XRUdVQVFiZnV0bVZHUkpDTFlBcmN1amkzOUhibnVqVHdFZ0tZb0pDaHBONm9hd21pYUROaHpEdzZXNGppS2FXVzJleTFWZG5fVnFF?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Shares Edge Down Ahead of ASCO Update", "summary": "Xenetic Biosciences shares edged down ahead of its ASCO poster session on June 1, where it will present research on targeting cfDNA and NETs to boost CAR-T cell activity. The company reported improved Q1 results with increased royalty revenue and a narrowed net loss, and is explo", "url": "https://www.bez-kabli.pl/xenetic-biosciences-stock-slips-before-asco-heres-what-traders-are-watching/", "source_name": "Bez Kabli", "published_at": "2026-05-22T10:05:00", "published_display": "22 May 2026 10:05", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contact Us \u2013 Inside INdiana Business - Xenetic Biosciences, Inc. - Common Stock (Nasdaq:XBIO) Stock Quote", "summary": "This page provides a detailed stock quote and news updates for Xenetic Biosciences, Inc. (Nasdaq: XBIO), showing its current price, trading volume, and performance metrics. It also features recent news releases about the company's financial results, clinical advancements, and col", "url": "https://markets.financialcontent.com/worldnow.insideindianabusiness/quote?Symbol=537%3A32683516", "source_name": "FinancialContent", "published_at": "2026-05-16T00:39:34", "published_display": "16 May 2026 00:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform", "summary": "", "url": "https://finance.yahoo.com/news/xenetic-biosciences-reports-first-quarter-120500104.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-13T12:05:00+00:00", "published_display": "13 May 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/xenetic-biosciences-q1-earnings-snapshot-205848103.html", "source_name": "Associated Press", "published_at": "2026-05-12T20:58:48+00:00", "published_display": "12 May 2026 20:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xenetic-biosciences-inc-announces-abstract-130000639.html", "source_name": "ACCESS Newswire", "published_at": "2026-04-22T13:00:00+00:00", "published_display": "22 Apr 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Xenetic Biosciences Earnings Notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQSGRYbU5DUWZweXpNZHJ1anllclFTRm1QVjFXdDhwRGFRYzFQaU56aFAxQnJKb19Oc2ozV3RkSnFkREUzbFBXbVJBb1NmYjRJc3Vnd0RLeE5nam9aUHFvRzBuenlqTmpPdzFHN0FRcHNOMS1DVjVjZVhqRlBZWHdkZkcydnBqT0hiYWx0S25xV05HRE9pWEZiQU9GQUFYU3l6TnhqUEtZQQ?oc=5", "source_name": "Trefis", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMjlHNTkzUk5CelI5cGlJckdLd2V0NGVZYVYxS01kVHg0TnZKOWRvQ1Vxc2E2U3JvNE1NRXFQOWdpeE9jZGpucHZ4c2htRG1Ld250QmJfOEZma0d5UmFzMGVTc1BSbUhmUEF1bXk0bkRYb3FzX0t5Q3NEbEw3SmxjYklla0xwRUhCa3FvUnZIbmg3b3hmNXNTdjZ6cE5uUS03WENsLVRYWGFZQ3B2MHAwQzBzSlRxLVNSUjh4U3JB?oc=5", "source_name": "The Stockton Record", "published_at": "2025-12-13T05:13:45+00:00", "published_display": "13 Dec 2025 05:13", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc. (XBIO) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5zb0FKZHpuLXVNM3hvbldyOFJ3Q1JYVl9kZ2duVTh1b1pOQnBLMkxDcjFYS1Zka0UzQ3RFLU8wR0NBT3I3bUFWUExpM0JHdw?oc=5", "source_name": "StocksToTrade", "published_at": "2025-10-08T14:25:18+00:00", "published_display": "08 Oct 2025 14:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Xenetic Biosciences (XBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTFB5aTFTRlJPc1dfODd2Rk1tMzJKbzRhZjhRNWRFZWpIc1BfZHdxOU1mNXAzS0FfOXVibDkzaFFlUThIVE83emxVLWhRRktYNTJzZVhWLVN2cWV0Z2had1c0UzlVTlFTdzNPLV9hcg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-08-12T07:00:00+00:00", "published_display": "12 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences (XBIO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBZLU9udnFYU3Y4UW1SY2xzaWlUS085VmpUMGRPVlI1T0FvMDBsT3JqUll5cHBZdVpGOUtOR2RrYXZzcWY3T3lpWXJkWTV0V3VoX0Nz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T16:47:18+00:00", "published_display": "24 Apr 2025 16:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIO: Xenetic Biosciences Inc Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE1lVS1faW5udHE0SlpzVklhYmpLc2xtTzVYMmlUcjNiWVZ2VXJuUTlsZmlKVS0ySXFtSVUxWEl4TUNkVkhTRHBjRDBR?oc=5", "source_name": "Stocktwits", "published_at": "2017-01-20T15:28:14+00:00", "published_display": "20 Jan 2017 15:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to book forward of Xenetic Biosciences, Inc. \u2013 NASDAQ:XBIO", "summary": "This page from TradingView displays financial information for Xenetic Biosciences, Inc. (NASDAQ: XBIO), specifically focusing on its \"Price to book forward\" metric. The content indicates that market data is provided by ICE Data Services, reference data by FactSet, and SEC filings", "url": "https://www.tradingview.com/symbols/NASDAQ-XBIO/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T16:10:49", "published_display": "09 Jul 2026 16:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Xenetic Biosciences, Inc. \u2013 NASDAQ:XBIO", "summary": "This article provides a financial data point for Xenetic Biosciences, Inc. (NASDAQ: XBIO), specifically its \"Price to sales forward\" metric. The content indicates that the market was closed at the time of viewing, with no trades apparent. It appears to be a snapshot from a financ", "url": "https://www.tradingview.com/symbols/NASDAQ-XBIO/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T04:10:42", "published_display": "09 Jul 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences (XBIO) Surges 6.14% as Stock Tests Key Resistance at $3.09 - Large Cap Trends", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxPN29tRDFpTzBkUU4zVW82dGp2S0hOZi1MUEp6NzBRa1NvbnZxd3VhZ1dDWDdVUEMzQ2dKdS1tXzktNVJ2TU1PUEU4V3BVVHR5cmpaM1F6ODJYSDNFcmVZcFlsSXpMOE1GWE9XR1YwcDEyT2gwcWpGZFFjM25qLUR1NEl3Qkd4aFVMbTJET2lYekZ6clhCbmtkQXo5c29ONVg3S3lrTTRWeWJGckR0RG53Wm5BTTNwSkk?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-06T15:47:40+00:00", "published_display": "06 Jul 2026 15:47", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIO - Xenetic Biosciences Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial overview for Xenetic Biosciences Inc. (XBIO). It includes key financial metrics, performance indicators, insider ownership details, and analyst recommendations. The data highlights the company's valuation, p", "url": "https://finviz.com/stock?t=XBIO&ta=1&p=d&ty=lf&r=ytd&page=3", "source_name": "Finviz", "published_at": "2026-07-04T10:40:19", "published_display": "04 Jul 2026 10:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIO - Xenetic Biosciences Inc Short Interest", "summary": "This article provides a detailed financial overview and short interest data for Xenetic Biosciences Inc. (XBIO). It includes key metrics such as market capitalization, income, sales, various ratios, and performance indicators spanning different timeframes, along with short intere", "url": "https://finviz.com/stock?t=XBIO&p=d&ty=si&r=ytd", "source_name": "Finviz", "published_at": "2026-07-04T09:40:19", "published_display": "04 Jul 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences, Inc. Actuals & Estimates (NASDAQ:XBIO)", "summary": "This article provides an overview of Xenetic Biosciences, Inc. (NASDAQ: XBIO) financials, including its current stock price, market capitalization, and earnings information. It highlights recent stock performance, historical highs and lows, and key financial metrics like EBITDA a", "url": "https://www.tradingview.com/symbols/NASDAQ-XBIO/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T14:10:54", "published_display": "25 Jun 2026 14:10", "sentiment": "negative", "sentiment_pct": 37, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "Xenetic Biosciences Inc (XBIO) has a current risk assessment score of 1.12, ranking 328 out of 387 in the Biotechnology & Medical Research industry. The company's beta is 2.12, indicating higher volatility compared to the S&P 500. Key risk metrics like maximum drawdown and volati", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-24T05:39:56", "published_display": "24 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Xenetic Biosciences Inc (XBIO), detailing its business segments, regional revenue, and profit contribution. However, the company has not yet disclosed the relevant data for these categories. The article includes current stock informat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/revenue", "source_name": "TradingKey", "published_at": "2026-06-23T19:39:40", "published_display": "23 Jun 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Xenetic Biosciences Inc (XBIO) has a robust financial status with a current financial score of 8.34, ranking 48th in the Biotechnology & Medical Research industry. The company reported a significant year-over-year revenue increase of 36.01% to $806.92K and a net profit increase o", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/financial-health", "source_name": "TradingKey", "published_at": "2026-06-23T08:11:02", "published_display": "23 Jun 2026 08:11", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Xenetic Biosciences Inc (XBIO), including its price momentum, support and resistance levels, and various technical indicators and moving averages. As of June 26, 2026, XBIO's stock price shows a current momentum score of 6.82 and is t", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/technical", "source_name": "TradingKey", "published_at": "2026-06-23T06:40:26", "published_display": "23 Jun 2026 06:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences (Nasdaq:XBIO) - Stock Analysis", "summary": "Xenetic Biosciences (Nasdaq:XBIO) is a biopharmaceutical company focusing on immune-oncology technologies to treat cancers, with a market capitalization of US$6.4 million. The company has reported recent improvements in reducing net losses and growing revenue in its recent quarte", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xbio/xenetic-biosciences", "source_name": "Simply Wall Street", "published_at": "2026-06-21T04:10:48", "published_display": "21 Jun 2026 04:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides historical data on dividends and stock splits for Xenetic Biosciences Inc (XBIO). It notes that XBIO has distributed $0.00 in dividends over the past five years and lists stock split events, all of which were a 10-for-1 merger occurring on May 12, 2023. The ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T08:40:12", "published_display": "19 Jun 2026 08:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Xenetic Biosciences Inc (XBIO), highlighting its current valuation score of 7.62 within the Biotechnology & Medical Research industry. It notes the company's current P/E ratio is -2.53, which is significantly below its recent high. Th", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:23", "published_display": "18 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Institutional Confidence", "summary": "Xenetic Biosciences Inc (XBIO) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. Institutional shareholding proportion decreased by 53.00% quarter-over-quarter to 4.97%. James Simons is the largest insti", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T11:10:23", "published_display": "18 Jun 2026 11:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc (XBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Xenetic Biosciences Inc (XBIO), noting that no earnings forecast score is currently available, unlike the industry average. It also details current stock performance, market capitalization, and various financial metrics. The company ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-xbio/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T10:39:21", "published_display": "18 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc. (XBIO) Q2 2025 Earnings: Narrowed Loss Beats Expectations, Pipeline Progress Key - Operating Income Trends", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOMkdPSEgwNHJvZHo4Zmo0dl9rczZMd1EzREkxOER5VVNZT1VzTm1oZ3lnWi1mNVRNeUp1VkpaczNwc0NmWnF4bUFDQl92SGU3QmpmcW5GWEFYTzdGUWVMYWVWeC1RTWFOaGJGY0dNak9SeDhqWW5HbUd6aXpwOFMtNE9KYWloRWlHdTFqc0g5ei03TTh4QVNSczRjak9OWldGQmhBUlhsUVlsSm1vbGNobnNVT2tDdDV6VkVzOExYX2pMS1VZY2R4LWpkcFJ0V2ZPREo3dVIyTEVGOGpqUkE?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 69, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences | 8-K: Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform", "summary": "This document is an 8-K filing from Xenetic Biosciences, reporting its financial results for the first quarter of 2026. The filing highlights the continued advancement of the company's DNase Oncology Platform. As an 8-K, it typically contains information deemed material or import", "url": "https://www.moomoo.com/news/notice/307292323/xenetic-biosciences-8-k-xenetic-biosciences-reports-first-quarter-2026", "source_name": "Moomoo", "published_at": "2026-06-06T22:10:24", "published_display": "06 Jun 2026 22:10", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma", "summary": "Xenetic Biosciences announced that its partner, PeriNess Ltd., received approval from the Israeli Ministry of Health to conduct an exploratory clinical study. This study will combine systemic DNase I with anti-CD19 CAR T cells in patients with large B-cell lymphoma (LBCL). The ap", "url": "https://www.marketscreener.com/news/xenetic-biosciences-inc-announces-that-its-collaboration-partner-received-approval-from-the-israel-ce7f5ddcde81f52d", "source_name": "www.marketscreener.com", "published_at": "2026-06-06T03:08:59", "published_display": "06 Jun 2026 03:08", "sentiment": "positive", "sentiment_pct": 74, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Israeli study to combine DNase I with CAR-T in large B-cell lymphoma", "summary": "Xenetic Biosciences' partner, PeriNess, has received approval from the Israeli Ministry of Health to conduct an exploratory clinical study combining systemic DNase I with anti-CD19 CAR T cells for large B-cell lymphoma (LBCL) patients. The trial, to be conducted at Tel-Aviv Soura", "url": "https://www.stocktitan.net/news/XBIO/xenetic-biosciences-inc-announces-that-its-collaboration-partner-dgcaoxvrgx4y.html", "source_name": "Stock Titan", "published_at": "2026-06-04T12:39:36", "published_display": "04 Jun 2026 12:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival", "summary": "Xenetic Biosciences announced positive preclinical data at ASCO 2026, showing that DNase I significantly enhances CAR-T cell expansion, persistence, and antitumor efficacy in aggressive hematologic cancer models. The findings demonstrate DNase I's potential as a transformative ad", "url": "https://www.biospace.com/press-releases/xenetic-biosciences-showcases-compelling-asco-2026-data-demonstrating-dnase-i-significantly-enhances-car-t-cell-persistence-tumor-control-and-survival", "source_name": "BioSpace", "published_at": "2026-06-02T21:09:23", "published_display": "02 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 76, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic presents preclinical data on DNase I with CAR-T therapy", "summary": "Xenetic Biosciences Inc. presented preclinical data showing that DNase I enhances CAR-T cell expansion and antitumor efficacy in hematologic cancer models. The studies demonstrated that DNase I degrades extracellular DNA, preserves CAR-T cell function, and improves tumor control,", "url": "https://www.investing.com/news/company-news/xenetic-presents-preclinical-data-on-dnase-i-with-cart-therapy-93CH-4719450", "source_name": "Investing.com", "published_at": "2026-06-01T13:09:33", "published_display": "01 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After CAR-T failure, DNase I tied to tumor decline in pediatric lymphoma case", "summary": "Xenetic Biosciences (NASDAQ: XBIO) presented preclinical and translational data at ASCO 2026 showing that its DNase I significantly improved CAR-T cell expansion, persistence, and tumor control in aggressive B cell malignancy models. The data also include observations from a pedi", "url": "https://www.stocktitan.net/news/XBIO/xenetic-biosciences-showcases-compelling-asco-2026-data-fq1m366f597g.html", "source_name": "Stock Titan", "published_at": "2026-06-01T13:09:32", "published_display": "01 Jun 2026 13:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences (XBIO) Q2 2025 Earnings: EPS Surprises to the Upside with Narrower-Than-Expected Loss - Revenue Recognition Risk", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4wFBVV95cUxQdFJKbUFja2Q0TEJNNDdxOGxnRlJVWUF2ZHJQUkRFUElNNXBDMXBhSUZqdE9PTkJScmwtd2tyYmJVdmJzMUFWV0NXZzBIeXlLVG1sTnhhT1cxRjJnQWdtX2dQUXU1ek9QSXRCQ2VMVUxSUEdQYTRNaWZRdWlYSFBaV05Qd0FOdTFiVkMwRHBsaFphSXV0bjMzV0ZYMzhzbnRSTUNSZE9takN6WU1CbS1Uc2Q0aENQYnhvYTZRNHJRbm9WNC1KLU5hQjVDR0xnR2VIeXBwYjlSdXRrQ193cDdMTHpnTQ?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-06-01T07:00:00+00:00", "published_display": "01 Jun 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIO - Xenetic Biosciences Inc Stock Price and Quote", "summary": "This page provides a comprehensive overview of Xenetic Biosciences Inc. (XBIO) stock, including its latest financial data, recent news, and analyst ratings. It details the company's financial performance, stock statistics, and a chronological list of press releases related to its", "url": "https://finviz.com/stock?t=XBIO", "source_name": "Finviz", "published_at": "2026-05-30T19:39:40", "published_display": "30 May 2026 19:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Michael Liu and MJL Manager LLC report stakes in Xenetic Biosciences (NASDAQ: XBIO)", "summary": "Michael Liu and MJL Manager LLC have reported their stakes in Xenetic Biosciences (NASDAQ: XBIO) through a Schedule 13G filing. MJL Manager LLC holds 93,565 shares, representing 4.1% of the class, while Michael Liu individually holds 126,741 shares, accounting for 5.5%. Michael L", "url": "https://www.stocktitan.net/sec-filings/XBIO/schedule-13g-xenetic-biosciences-inc-passive-investment-disclosure-5-93ca949c0c13.html", "source_name": "Stock Titan", "published_at": "2026-05-29T19:39:20", "published_display": "29 May 2026 19:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences (XBIO) Edges Lower Amid Tight Trading Range - KAMA Signal", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPUWNxWW9iMmFlV1JENnRqM3JoNGp0QTl3QUk2aDc2cjA1LV9GYTZxM0lENERhX1dtOF9JYWlUM2IySjJRTm5UWWJGdFUxaHFqM0NmbEwzdC1XRUdVQVFiZnV0bVZHUkpDTFlBcmN1amkzOUhibnVqVHdFZ0tZb0pDaHBONm9hd21pYUROaHpEdzZXNGppS2FXVzJleTFWZG5fVnFF?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-27T07:00:00+00:00", "published_display": "27 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Shares Edge Down Ahead of ASCO Update", "summary": "Xenetic Biosciences shares edged down ahead of its ASCO poster session on June 1, where it will present research on targeting cfDNA and NETs to boost CAR-T cell activity. The company reported improved Q1 results with increased royalty revenue and a narrowed net loss, and is explo", "url": "https://www.bez-kabli.pl/xenetic-biosciences-stock-slips-before-asco-heres-what-traders-are-watching/", "source_name": "Bez Kabli", "published_at": "2026-05-22T10:05:00", "published_display": "22 May 2026 10:05", "sentiment": "negative", "sentiment_pct": 38, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Contact Us \u2013 Inside INdiana Business - Xenetic Biosciences, Inc. - Common Stock (Nasdaq:XBIO) Stock Quote", "summary": "This page provides a detailed stock quote and news updates for Xenetic Biosciences, Inc. (Nasdaq: XBIO), showing its current price, trading volume, and performance metrics. It also features recent news releases about the company's financial results, clinical advancements, and col", "url": "https://markets.financialcontent.com/worldnow.insideindianabusiness/quote?Symbol=537%3A32683516", "source_name": "FinancialContent", "published_at": "2026-05-16T00:39:34", "published_display": "16 May 2026 00:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform", "summary": "", "url": "https://finance.yahoo.com/news/xenetic-biosciences-reports-first-quarter-120500104.html", "source_name": "ACCESS Newswire", "published_at": "2026-05-13T12:05:00+00:00", "published_display": "13 May 2026 12:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences: Q1 Earnings Snapshot", "summary": "", "url": "https://finance.yahoo.com/news/xenetic-biosciences-q1-earnings-snapshot-205848103.html", "source_name": "Associated Press", "published_at": "2026-05-12T20:58:48+00:00", "published_display": "12 May 2026 20:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/xenetic-biosciences-inc-announces-abstract-130000639.html", "source_name": "ACCESS Newswire", "published_at": "2026-04-22T13:00:00+00:00", "published_display": "22 Apr 2026 13:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Earnings Notes", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQSGRYbU5DUWZweXpNZHJ1anllclFTRm1QVjFXdDhwRGFRYzFQaU56aFAxQnJKb19Oc2ozV3RkSnFkREUzbFBXbVJBb1NmYjRJc3Vnd0RLeE5nam9aUHFvRzBuenlqTmpPdzFHN0FRcHNOMS1DVjVjZVhqRlBZWHdkZkcydnBqT0hiYWx0S25xV05HRE9pWEZiQU9GQUFYU3l6TnhqUEtZQQ?oc=5", "source_name": "Trefis", "published_at": "2025-12-15T08:00:00+00:00", "published_display": "15 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNMjlHNTkzUk5CelI5cGlJckdLd2V0NGVZYVYxS01kVHg0TnZKOWRvQ1Vxc2E2U3JvNE1NRXFQOWdpeE9jZGpucHZ4c2htRG1Ld250QmJfOEZma0d5UmFzMGVTc1BSbUhmUEF1bXk0bkRYb3FzX0t5Q3NEbEw3SmxjYklla0xwRUhCa3FvUnZIbmg3b3hmNXNTdjZ6cE5uUS03WENsLVRYWGFZQ3B2MHAwQzBzSlRxLVNSUjh4U3JB?oc=5", "source_name": "The Stockton Record", "published_at": "2025-12-13T05:13:45+00:00", "published_display": "13 Dec 2025 05:13", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences Inc. (XBIO) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTkFVX3lxTE5zb0FKZHpuLXVNM3hvbldyOFJ3Q1JYVl9kZ2duVTh1b1pOQnBLMkxDcjFYS1Zka0UzQ3RFLU8wR0NBT3I3bUFWUExpM0JHdw?oc=5", "source_name": "StocksToTrade", "published_at": "2025-10-08T14:25:18+00:00", "published_display": "08 Oct 2025 14:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should I buy Xenetic Biosciences (XBIO)", "summary": "", "url": "https://news.google.com/rss/articles/CBMibEFVX3lxTFB5aTFTRlJPc1dfODd2Rk1tMzJKbzRhZjhRNWRFZWpIc1BfZHdxOU1mNXAzS0FfOXVibDkzaFFlUThIVE83emxVLWhRRktYNTJzZVhWLVN2cWV0Z2had1c0UzlVTlFTdzNPLV9hcg?oc=5", "source_name": "Zacks Investment Research", "published_at": "2025-08-12T07:00:00+00:00", "published_display": "12 Aug 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Xenetic Biosciences (XBIO) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTFBZLU9udnFYU3Y4UW1SY2xzaWlUS085VmpUMGRPVlI1T0FvMDBsT3JqUll5cHBZdVpGOUtOR2RrYXZzcWY3T3lpWXJkWTV0V3VoX0Nz?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-24T16:47:18+00:00", "published_display": "24 Apr 2025 16:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "XBIO: Xenetic Biosciences Inc Latest Stock Price, Analysis, News and Trading Ideas", "summary": "", "url": "https://news.google.com/rss/articles/CBMiSkFVX3lxTE1lVS1faW5udHE0SlpzVklhYmpLc2xtTzVYMmlUcjNiWVZ2VXJuUTlsZmlKVS0ySXFtSVUxWEl4TUNkVkhTRHBjRDBR?oc=5", "source_name": "Stocktwits", "published_at": "2017-01-20T15:28:14+00:00", "published_display": "20 Jan 2017 15:28", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 45, "sentiment_summary": {"positive": 14, "negative": 7, "neutral": 24, "score": 55, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 76, "events": [{"event": "general", "label": "Market update", "weight": 10.8, "count": 19}, {"event": "earnings", "label": "Earnings", "weight": 10.8, "count": 21}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 7}, "market_context": {"has_market_context": true, "latest_close": 2.73, "latest_week": "2026-07-10", "one_week_move": -1.3, "four_week_move": -14.5, "twelve_week_move": -22.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": -0.409391, "market_dynamics_buy_signal": false, "relative_strength": -20.465069, "fair_value_gap": -22.1, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 48.7706, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-1.3% over one week, -14.5% over four weeks, trend active, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 8}, {"label": "Market source", "count": 5}, {"label": "TradingView", "count": 4}, {"label": "Stock Titan", "count": 4}, {"label": "dars.gov.et", "count": 3}, {"label": "Finviz", "count": 3}, {"label": "simplywall.st", "count": 2}, {"label": "ACCESS Newswire", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 37}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 21}, {"label": "Market update", "count": 19}, {"label": "Analyst action", "count": 2}, {"label": "Regulatory and legal", "count": 2}, {"label": "Deals and strategy", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "76/100 classification confidence."}, {"label": "Company focus", "value": "37", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-1.3% over one week, -14.5% over four weeks, trend active, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to book forward of Xenetic Biosciences, Inc. \u2013 NASDAQ:XBIO"}], "updated_at": "2026-07-16T02:16:20.413175+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}